Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BY-NC-ND 4.0Journal of Translational Medicine

Epitranscriptomic regulation in cholangiocarcinoma: mechanisms and therapeutic implications

  1. 1Department of Hepatobiliary Pancreatic Tumor Center, Chongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis, Chongqing University Cancer Hospital, Chongqing, 400030 China
  2. 2Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298 USA

Abstract

Cholangiocarcinoma (CCA) is the second most common primary liver cancer. It is highly invasive, shows early metastasis, and frequently recurs after surgery. These features result in poor clinical outcomes and limited treatment options. Increasing evidence indicates that epigenetic dysregulation plays a key role in the initiation and progression of CCA. Epigenetic modifications include covalent changes to DNA, RNA, and histone proteins. These modifications regulate chromatin structure and gene expression, thereby shaping malignant cellular behavior. Recent studies have shown that epigenetic regulatory networks are widely disrupted in CCA. This disruption leads to both transcriptional and post-transcriptional reprogramming, which promotes tumor growth, invasion, and therapeutic resistance. Among these mechanisms, epitranscriptomic regulation has emerged as an important layer of gene expression control. RNA modifications, such as m6A and other chemical marks, influence RNA stability, splicing, translation, and degradation. These processes contribute to tumor initiation and progression. In this review, we summarize recent advances in epitranscriptomic regulation in CCA. We highlight key regulatory mechanisms and their functional roles in tumor biology. A better understanding of these pathways may provide new biomarkers and therapeutic targets for CCA.

Related

  1. 106 Multiplex epitranscriptomic profiling reveals RNA modification signatures of immune activation and therapeutic response in cancer immunology
    Eric Davis, Ananya Anmangandla, Ayush Raman +3
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textMolecular biology & gene regulationDOAJ
  2. Extracellular vesicles in the immune regulation of hematological malignancies: mechanisms, prognostic significance, and therapeutic opportunities
    Tuya Wang, Jing Fu, Ye Huang +2
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  3. N6-Methyladenosine and 5-Methylcytosine Epitranscriptomic Regulation of Male Reproduction and Fertility.
    Sana M Salih, Ayman Al-Hendy, Qiwei Yang
    BiologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  4. A DRACH Observed/Expected Metric Reveals the Evolutionary Landscape of Epitranscriptomic Regulation Across Bilateria
    Natacha Clairet, Jérémy Le Luyer, Hélène Auger +2
    Annals of the New York Academy of SciencesPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationHAL
  5. Histone Acetylation in Bone Remodeling: Metabolic Regulation, Lineage-Specific Chromatin Programs, and Therapeutic Implications
    Jianhong Dong, Xianji Wei, Yifan Qian +2
    CellsPeer-reviewedCC BY 4.0Molecular biology & gene regulationCrossref
BibTeX
@article{liu2026epitranscriptomic,
  title = {{Epitranscriptomic regulation in cholangiocarcinoma: mechanisms and therapeutic implications}},
  author = {Maoyun Liu and Fengsheng Dai and Sheng Wang and Yi Wang and Cheng Zhang and Yuqin Xie and Ai Shen and Hengbin Wang and Dewei Li and Hui Li},
  journal = {Journal of Translational Medicine},
  year = {2026},
  month = aug,
  doi = {10.1186/s12967-026-08740-8},
  url = {https://doi.org/10.1186/s12967-026-08740-8},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Epitranscriptomic regulation in cholangiocarcinoma: mechanisms and therapeutic implications
AU  - Maoyun Liu
AU  - Fengsheng Dai
AU  - Sheng Wang
AU  - Yi Wang
AU  - Cheng Zhang
AU  - Yuqin Xie
AU  - Ai Shen
AU  - Hengbin Wang
AU  - Dewei Li
AU  - Hui Li
PY  - 2026
DA  - 2026/08/11
JO  - Journal of Translational Medicine
DO  - 10.1186/s12967-026-08740-8
UR  - https://doi.org/10.1186/s12967-026-08740-8
AB  - Cholangiocarcinoma (CCA) is the second most common primary liver cancer. It is highly invasive, shows early metastasis, and frequently recurs after surgery. These features result in poor clinical outcomes and limited treatment options. Increasing evidence indicates that epigenetic dysregulation plays a key role in the initiation and progression of CCA. Epigenetic modifications include covalent changes to DNA, RNA, and histone proteins. These modifications regulate chromatin structure and gene expression, thereby shaping malignant cellular behavior. Recent studies have shown that epigenetic regulatory networks are widely disrupted in CCA. This disruption leads to both transcriptional and post-transcriptional reprogramming, which promotes tumor growth, invasion, and therapeutic resistance. Among these mechanisms, epitranscriptomic regulation has emerged as an important layer of gene expression control. RNA modifications, such as m6A and other chemical marks, influence RNA stability, splicing, translation, and degradation. These processes contribute to tumor initiation and progression. In this review, we summarize recent advances in epitranscriptomic regulation in CCA. We highlight key regulatory mechanisms and their functional roles in tumor biology. A better understanding of these pathways may provide new biomarkers and therapeutic targets for CCA.
SN  - 1479-5876
ER  -